• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

ResApp Expands Research Collaboration With Mass General for Diagnostic App

by Jasmine Pennic 01/11/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

ResApp Nabs $12.5M For Smartphone App That Instantly Diagnose Respiratory Diseases

ResApp, a Australian-based digital health startup that has developed a smartphone app that can diagnose respiratory diseases based on the sound signatures of the coughs has entered into a two-year expanded research collaboration with Massachusetts General Hospital (MGH). As part of the research collaboration, ResApp and MGH will perform additional analysis of the SMARTCOUGH-C study data, use the SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical practice today and evaluate the efficacy of ResApp’s cough-based diagnostic test in additional respiratory disease indications. 

SMARTCOUGH-C builds on ResApp’s highly successful Australian pediatric clinical study that demonstrated accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections. The technology is currently recruiting patients for its US study with locations at Massachusetts General Hospital, The Cleveland Clinic and Texas Children’s Hospital.

Dr. Peter Moschovis M.D., MPH has been appointed to lead the team at MGH. Dr. Moschovis undertook his specialist training at Harvard Medical School and has a joint appointment in pediatrics and pulmonary/critical care at MGH. Dr. Moschovis is a global health researcher in the Division of Global Health at MGH.

“We are delighted to expand our relationship with Dr. Moschovis and MGH beyond the SMARTCOUGH-C study to diagnose additional diseases and to evaluate clinical practices. The more broadly and effectively we apply ResApp’s technology with our partners, the more rapidly we will integrate our diagnostic test into current clinical practice,” said Tony Keating, CEO and Managing Director of ResApp Health.

The company recently announced the start of US clinical studies of this software to diagnose respiratory disease in kids simply from a cough into a smart phone. The large, prospective, double-blind, multi-site clinical study aims to recruit up to 1,111 patients between the ages of 29 weeks and 12 years. The co-primary efficacy endpoints of the study are the diagnosis of pneumonia compared to radiologic and clinical diagnosis. Secondary endpoints are diagnosis of other common childhood respiratory diseases such as upper respiratory tract infection, croup, bronchiolitis and asthma compared with a clinical diagnosis.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: ResApp, respiratory Apps, respiratory medicine

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

The AI Paradox in Healthcare: Notable CEO Shares Why Moving Too Slowly is a Greater Risk

Most-Read

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Patient Square Capital Acquires Premier in $2.6B Deal

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |